This form contains the measure information submitted by stewards. Blank fields indicate no information was provided. Attachments also may have been submitted and are provided to reviewers. The subcriteria and most of the footnotes from the evaluation criteria are provided in Word comments within the form and will appear if your cursor is over the highlighted area. Hyperlinks to the evaluation criteria and ratings are provided in each section.

TAP/Workgroup (if utilized): Complete all yellow highlighted areas of the form. Evaluate the extent to which each subcriterion is met. Based on your evaluation, summarize the strengths and weaknesses in each section.

Note: If there is no TAP or workgroup, the SC also evaluates the subcriteria (yellow highlighted areas).

Steering Committee: Complete all pink highlighted areas of the form. Review the workgroup/TAP assessment of the subcriteria, noting any areas of disagreement; then evaluate the extent to which each major criterion is met; and finally, indicate your recommendation for the endorsement. Provide the rationale for your ratings.

Evaluation ratings of the extent to which the criteria are met
C = Completely (unquestionably demonstrated to meet the criterion)
P = Partially (demonstrated to partially meet the criterion)
M = Minimally (addressed BUT demonstrated to only minimally meet the criterion)
N = Not at all (NOT addressed; OR incorrectly addressed; OR demonstrated to NOT meet the criterion)
NA = Not applicable (only an option for a few subcriteria as indicated)

---

### MEASURE DESCRIPTIVE INFORMATION

<table>
<thead>
<tr>
<th>De.1 Measure Title:</th>
<th>In-hospital mortality following elective   open repair of AAAs</th>
</tr>
</thead>
<tbody>
<tr>
<td>De.2 Brief description of measure:</td>
<td>Percentage of asymptomatic patients undergoing open repair of abdominal aortic aneurysms (AAA) who die while in hospital. This measure is proposed for both hospitals and individual providers.</td>
</tr>
<tr>
<td>1.1-2 Type of Measure:</td>
<td>Outcome</td>
</tr>
<tr>
<td>De.3 If included in a composite or paired with another measure, please identify composite or paired measure</td>
<td>Submitted SVS measure: In-hospital mortality following elective endovascular repair of AAAs</td>
</tr>
<tr>
<td>De.4 National Priority Partners Priority Area:</td>
<td>Population health, Safety, Overuse</td>
</tr>
<tr>
<td>De.5 IOM Quality Domain:</td>
<td>Effectiveness, Efficiency, Safety</td>
</tr>
<tr>
<td>De.6 Consumer Care Need:</td>
<td>Staying healthy</td>
</tr>
</tbody>
</table>

### CONDITIONS FOR CONSIDERATION BY NQF

Four conditions must be met before proposed measures may be considered and evaluated for suitability as voluntary consensus standards:

A. The measure is in the public domain or an intellectual property (measure steward agreement) is signed. Public domain only applies to governmental organizations. All non-government organizations must sign a measure steward agreement even if measures are made publicly and freely available.

A.1 Do you attest that the measure steward holds intellectual property rights to the measure and the right to use aspects of the measure owned by another entity (e.g., risk model, code set)? Yes

A.2 Indicate if Proprietary Measure (as defined in measure steward agreement):

A.3 Measure Steward Agreement: Agreement will be signed and submitted prior to or at the time of measure submission

A.4 Measure Steward Agreement attached: Agreement With Measure Stewards_Agreement

---

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable
### B. The measure owner/steward verifies there is an identified responsible entity and process to maintain and update the measure on a schedule that is commensurate with the rate of clinical innovation, but at least every 3 years.  Yes, information provided in contact section

| C. The intended use of the measure includes both public reporting and quality improvement. | C | Y | N |

#### Purpose: Payment Program

| D. The requested measure submission information is complete.  Generally, measures should be fully developed and tested so that all the evaluation criteria have been addressed and information needed to evaluate the measure is provided.  Measures that have not been tested are only potentially eligible for a time-limited endorsement and in that case, measure owners must verify that testing will be completed within 12 months of endorsement. | D | Y | N |

**D.1 Testing:** Yes, fully developed and tested

**D.2 Have NQF-endorsed measures been reviewed to identify if there are similar or related measures?**

(for NQF staff use) Have all conditions for consideration been met?

Staff Notes to Steward (if submission returned):

Staff Notes to Reviewers (issues or questions regarding any criteria):

Staff Reviewer Name(s):

---

### TAP/Workgroup Reviewer Name:

| Steering Committee Reviewer Name: |

---

#### 1. IMPORTANCE TO MEASURE AND REPORT

Extent to which the specific measure focus is important to making significant gains in health care quality (safety, timeliness, effectiveness, efficiency, equity, patient-centeredness) and improving health outcomes for a specific high impact aspect of healthcare where there is variation in or overall poor performance. **Measures must be judged to be important to measure and report in order to be evaluated against the remaining criteria.**

#### Eval Rating

1a. High Impact

**(for NQF staff use) Specific NPP goal:**

| 1a.1 Demonstrated High Impact Aspect of Healthcare: Affects large numbers, Frequently performed procedure, Leading cause of morbidity/mortality, High resource use, Severity of Illness, Patient/societal consequences of poor quality |

1a.2

1a.3 Summary of Evidence of High Impact: An international population-based study found that an aneurysm was present in 8.9% of men and 2.2% women (p < 0.001). (1)

In the United States, ruptured AAAs are the 15th leading cause of death overall and the 10th leading cause of death in males over 55 years, a rate than has held steady for the past 2 decades. (2) Ruptured aneurysms are fatal in about 80% of cases. (3)


| 1b. Opportunity for Improvement |

| 1b.1 Benefits (improvements in quality) envisioned by use of this measure: Elective AAA repair is offered to prolong life by avoiding AAA rupture, which is fatal in more than 85% of cases. Rupture risk is primarily |

Rating: C=Completely; P=Partially; M=Minimally; N=Not at all; NA=Not applicable
assess by AAA diameter, with larger AAAs more prone to rupture. Surgical treatment carries risk, however, of mortality and morbidity, which must be balanced against the risk of rupture in order to determine which patients will benefit from elective repair.

Based on the UK aneurysm trial, the accepted diameter threshold for elective AAA repair is 5.5 cm, although women have a slightly higher risk than men, so a threshold of 5 cm is usually recommended for women. The key concept of this proposed measure is that patients who are at low risk for AAA rupture (<6 cm dia in men and <5.5 cm dia in women) should ONLY be offered elective AAA repair if their predicted operative mortality is low. This concept avoids the need for risk adjustment, since this is implicit in the decision to offer elective repair of AAAs. This measure will highlight variation in proper patient selection by reporting unadjusted mortality rates for surgery in patients with small AAAs in whom this rate should be universally low. Providers or hospitals with high mortality rates are either not performing safe surgery or are not properly selecting low risk patients. The measure specifically excludes patients with larger AAAs because risk adjustment would be needed for such cases, and accepted risk adjustment algorithms are not available.

1b.2 Summary of data demonstrating performance gap (variation or overall poor performance) across providers:
There is significant regional variation in rates of open AAA repair, indicating a performance gap. In 27 hospital referral regions, rates of AAA repair were at least 30% higher than the United States average of 1.0 per 1,000 Medicare enrollees. In 44 hospital referral regions, rates were more than 25% lower than the national average. (1)

Where these data have been monitored and reported to providers in VSGNE since 2003, among 12 centers and 55 providers treating 1289 patients with small AAAs the median mortality rate for men and women with small AAAs as defined above is 0%, but the range is 0-10%, indicating both a performance gap and opportunity for further improvement.

1b.3 Citations for data on performance gap:

1b.4 Summary of Data on disparities by population group:
Such data will become available if this measure is adopted for reporting and used by more centers with more varied population demographics than found in the New England region.

1b.5 Citations for data on Disparities:
not available

1c. Outcome or Evidence to Support Measure Focus

1c.1 Relationship to Outcomes (For non-outcome measures, briefly describe the relationship to desired outcome. For outcomes, describe why it is relevant to the target population): discussed above

1c.2-3. Type of Evidence: Cohort study, Expert opinion, Meta-analysis

1c.4 Summary of Evidence (as described in the criteria; for outcomes, summarize any evidence that healthcare services/care processes influence the outcome):
The endpoint of inhospital mortality is the accepted primary endpoint for both elective AAA repair. Variation in outcome has been established in randomized trials, cohort studies and meta analyses. This outcome measure has face validity among all providers of this service. Studies cited above have shown substantial variation in outcomes by provider when elective AAA repair is performed in patients with AAAs.

1c.5 Rating of strength/quality of evidence (also provide narrative description of the rating and by whom):
Mortality is the reporting standard recommended by the Society for Vascular Surgery, and has been used in multiple RCTs.
1c.6 Method for rating evidence: **Expert opinion.**

1c.7 Summary of Controversy/Contradictory Evidence: **None**


1c.9 Quote the Specific guideline recommendation (including guideline number and/or page number): **None**

1c.10 Clinical Practice Guideline Citation: **None**

1c.11 National Guideline Clearinghouse or other URL: **None**

1c.12 Rating of strength of recommendation (also provide narrative description of the rating and by whom): N/A

1c.13 Method for rating strength of recommendation (if different from USPSTF system, also describe rating and how it relates to USPSTF): N/A

1c.14 Rationale for using this guideline over others: Mortality is the accepted endpoint used in all trials. Restricting the AAA risk by confining the analysis to small or moderate AAAs is explained above.

| TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Importance to Measure and Report? | 1 |
| --- |
| Steering Committee: Was the threshold criterion, Importance to Measure and Report, met? Rationale: | Y |

2. SCIENTIFIC ACCEPTABILITY OF MEASURE PROPERTIES

Extent to which the measure, as specified, produces consistent (reliable) and credible (valid) results about the quality of care when implemented. (evaluation criteria)

<table>
<thead>
<tr>
<th>2a. MEASURE SPECIFICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>S.1 Do you have a web page where current detailed measure specifications can be obtained?</td>
</tr>
<tr>
<td>S.2 If yes, provide web page URL:</td>
</tr>
</tbody>
</table>

2a. Precisely Specified

2a.1 Numerator Statement (Brief, text description of the numerator - what is being measured about the target population, e.g. target condition, event, or outcome): Mortality following elective open repair of asymptomatic AAAs in men with < 6 cm dia and women with < 5.5 cm dia AAAs

2a.2 Numerator Time Window (The time period in which cases are eligible for inclusion in the numerator): Since hospitals have sufficient annual volume to generate accurate reporting levels, these are proposed for reporting every 12 months for hospital. Since surgeons have lower individual volume, we recommend annual reporting of the last 50 consecutive procedures, which may span more than one year, with suppression if < 10 procedures (ie, reported as too low volume to report).

2a.3 Numerator Details (All information required to collect/calculate the numerator, including all codes, logic, and definitions):
ANY registry that includes hospitalization details, AAA diameter and discharge status is required to identify patients for numerator inclusion. The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI) and the Vascular Study Group of New England (VSGNE) are examples of registries that record such information, but the measure is not limited to these registries. Patients who died in hospital following elective open infrarenal AAA repair if their aneurysm was asymptomatic (< 6 cm dia in men, < 5.5 cm dia in women, judged by preoperative imaging (CT, MR or ultrasound)). ANY registry that includes hospitalization details, AAA diameter and discharge status is required to identify patients for numerator inclusion. The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI) and the Vascular Study Group of New England (VSGNE) are examples of registries that record such information, but the measure is not limited to these registries. Patients who died in hospital following elective open infrarenal AAA repair if their aneurysm was asymptomatic and small (< 6 cm dia in men, < 5.5 cm dia in women, judged by preoperative imaging (CT, MR or ultrasound)).

2a.4 Denominator Statement (*Brief, text description of the denominator - target population being measured*):
All elective open repairs of asymptomatic AAAs in men with < 6 cm dia and women with < 5.5 cm dia AAAs

2a.5 Target population gender: Female, Male
2a.6 Target population age range: 18 years or older

2a.7 Denominator Time Window (*The time period in which cases are eligible for inclusion in the denominator*):
Since hospitals have sufficient annual volume to generate accurate reporting levels, these are proposed for reporting every 12 months for hospital. Since surgeons have lower individual volume, we recommend annual reporting of the last 50 consecutive procedures, which may span more than one year, with suppression if < 10 procedures (ie, reported as too low volume to report).

2a.8 Denominator Details (*All information required to collect/calculate the denominator - the target population being measured - including all codes, logic, and definitions*):
ANY registry that includes hospitalization details, AAA diameter and discharge status is required to identify patients for denominator inclusion. The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI) and the Vascular Study Group of New England (VSGNE) are examples of registries that record such information, but the measure is not limited to these registries. Patients who underwent elective open AAA repair are included if their aneurysm was asymptomatic (< 6 cm dia in men, < 5.5 cm dia in women, judged by preoperative imaging (CT, MR or ultrasound)).

2a.9 Denominator Exclusions (*Brief text description of exclusions from the target population*): = 6 cm minor diameter - men = 5.5 cm minor diameter - women Symptomatic AAAs that required urgent/emergent (non-elective) repair

2a.10 Denominator Exclusion Details (*All information required to collect exclusions to the denominator, including all codes, logic, and definitions*):
Patients undergoing non-elective open repair of symptomatic AAAs or those with AAAs larger than the diameters noted above.

2a.11 Stratification Details/Variables (*All information required to stratify the measure including the stratification variables, all codes, logic, and definitions*):
Not required

2a.12-13 Risk Adjustment Type: No risk adjustment necessary

2a.14 Risk Adjustment Methodology/Variables (*List risk adjustment variables and describe conceptual models, statistical models, or other aspects of model or method*):
See "Scientific Acceptability" section for rationale

2a.15-17 Detailed risk model available Web page URL or attachment:

2a.18-19 Type of Score: Rate/proportion
2a.20 Interpretation of Score: Better quality = Lower score
### 2a.21 Calculation Algorithm
*(Describe the calculation of the measure as a flowchart or series of steps)*:
Identify denominator, exclude non-elective repair of symptomatic or ruptured patients and men with AAA >6 cm, and women with AAA >5.5, find number of deaths
Outcome = deaths/ # cases

### 2a.22 Describe the method for discriminating performance *(e.g., significance testing)*:
Standard statistical comparison of rates to provide confidence levels to discriminate meaningful differences from the mean.

### 2a.23 Sampling (Survey) Methodology
*If measure is based on a sample (or survey), provide instructions for obtaining the sample, conducting the survey and guidance on minimum sample size (response rate)*:
N/A

### 2a.24 Data Source
*(Check the source(s) for which the measure is specified and tested)*
Electronic Clinical Data: Registry

### 2a.25 Data source/data collection instrument
*(Identify the specific data source/data collection instrument, e.g. name of database, clinical registry, collection instrument, etc.)*:
Society for Vascular Surgery Vascular Quality Initiative Registry
Vascular Study Group of New England Registry

### 2a.26-28 Data source/data collection instrument reference web page URL or attachment:
Attachment Open_AAA_Repair_v1.9.xlsx

### 2a.29-31 Data dictionary/code table web page URL or attachment:
Attachment OPEN AAA defs v.01.09.doc

### 2a.32-35 Level of Measurement/Analysis
*(Check the level(s) for which the measure is specified and tested)*
Clinician: Group/Practice, Clinician: Individual, Facility

### 2a.36-37 Care Settings
*(Check the setting(s) for which the measure is specified and tested)*
Hospital/Acute Care Facility

### 2a.38-41 Clinical Services
*(Healthcare services being measured, check all that apply)*
Clinicians: Physicians (MD/DO)

### TESTING/ANALYSIS

#### 2b. Reliability testing

#### 2b.1 Data/sample *(description of data/sample and size)*:
A random sample of 100 patient records representing 5 procedures relevant to the measure from 5 different hospitals based on data collected during the past 2 years. In addition, in-hospital mortality was examined by claims based analysis of 7,205 patients discharged and recorded in the VSGNE registry between 2003 to 2007.

#### 2b.2 Analytic Method *(type of reliability & rationale, method for testing)*:
A nurse abstractor completed a form based on medical record review for the variables relevant to this measure. The results of this chart review were then compared with the original registry data. The Kappa statistic was used to judge reliability of the data. For mortality validation, claims data from each of 12 hospitals were matched to patient identified data within the VSGNE registry to compare discharge status (alive vs. dead). Any discrepancies were then further evaluated based on a medical record audit.

#### 2b.3 Testing Results *(reliability statistics, assessment of adequacy in the context of norms for the test conducted)*:
The key variables for this measure and testing results were:

1. Correct procedure (open infrarenal AAA repair) performed. Kappa = 1.0
2. AAA diameter: Based on 60 measurement, the mean diameter was 56.7 mm in the registry, 56.6 mm in
the chart audit, no significant difference. Further, in on cases was the category of size based on the cut points of 6 cm in men and 5.5 cm in women different, Kappa = 1.0 for these categories.

3. Hospital mortality: Kappa = .91 (SE .01)

4. Elective(vs urgent or emergent); Kappa=1.0

2c. Validity testing

2c.1 Data/sample (description of data/sample and size): See reliability testing

2c.2 Analytic Method (type of validity & rationale, method for testing):
comparison of rates with published literature

2c.3 Testing Results (statistical results, assessment of adequacy in the context of norms for the test conducted):
In VSGNE, in hospital mortality for open AAA repair is 4-8%, and shows appropriate variation among hospitals, using this measure. This corresponds well to the published literature for elective AAA repair.

2d. Exclusions Justified

2d.1 Summary of Evidence supporting exclusion(s):
Large clinical trials have demonstrated the relative safety of observation AAAs with a minimum diameter of less than 5.5 cm. Most of these data were from men, and the same studies show that for women, AAAs rupture risk is higher, such that a minimum 5 cm threshold for women is generally recommended. In this measure, we are proposing that elective open AAA repair in men with AAAs < 6 cm dia and women with AAAs < 5.5 cm dia should only be recommended when the operative risk is low, because the AAA rupture risk is low (at a size less than 0.5 greater than the minimum rupture risk). This means that risk adjustment is considered as part of the surgical decision making, and does not need to be otherwise controlled for, as discussed further in 2.e.1.

2d.2 Citations for Evidence:

2d.3 Data/sample (description of data/sample and size): 1201 patients undergoing open elective AAA repair in VSGNE, all patients (ie, all AAA diameters treated), 2003-2010. 886 men, 315 women

2d.4 Analytic Method (type analysis & rationale):
rate calculation based on AAA dia size. AAAs were analyzed with 6 cm dia cutpoint in men and a 5.5 cm dia cutpoint in women, as described below.

2d.5 Testing Results (e.g., frequency, variability, sensitivity analyses):
Men, < 6cm AAA, mdn 0% mortality, range 0-4.1% among 10 centers
Men, >= 6 cm dia, mdn 0% mortality, range 0-10.4% among 10 centers

Women, < 5.5 cm dia AAAs, mdn mortality 0%, range 0-10% among 9 centers
Women, >= 5.5 cm dia AAAs, mdn mortality 1.1%, range 0-20% among 9 centers

2e. Risk Adjustment for Outcomes/ Resource Use Measures

2e.1 Data/sample (description of data/sample and size): This measure was designed to avoid the need for risk adjustment, because risk adjustment is complex for AAA repair, and accepted algorithms do not yet exist. In patients with AAAs, with low rupture risk, it is incumbent on the surgeon to factor in the risk-benefit of elective, prophylactic repair, since a high operative mortality will eliminate any benefit of AAA repair. Women have higher rupture risk than men, so by focusing this measure on AAAs < 5.5 cm in women and < 6 cm in men, the non-risk-adjusted mortality is a fair comparison of surgical outcome in the opinion of the sponsor, the Society for Vascular Surgery, and it represents a very important outcome to measure.

2e.2 Analytic Method (type of risk adjustment, analysis, & rationale):
N/A
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>2e.3</td>
<td><strong>Testing Results</strong> <em>(risk model performance metrics)</em>: N/A</td>
</tr>
<tr>
<td>2e.4</td>
<td>If outcome or resource use measure is not risk adjusted, provide rationale: N/A</td>
</tr>
<tr>
<td>2f.1</td>
<td><strong>Data/sample from Testing or Current Use</strong> <em>(description of data/sample and size)</em>: see section 1.b.3 and above 2.d,5</td>
</tr>
<tr>
<td>2f.2</td>
<td>Methods to identify statistically significant and practically/meaningfully differences in performance <em>(type of analysis &amp; rationale)</em>: Standard statistical analysis to determine 95% confidence interval for hospitals and providers to determine practical difference from mean</td>
</tr>
<tr>
<td>2f.3</td>
<td><strong>Provide Measure Scores from Testing or Current Use</strong> <em>(description of scores, e.g., distribution by quartile, mean, median, SD, etc.; identification of statistically significant and meaningfully differences in performance)</em>:</td>
</tr>
<tr>
<td>2g.1</td>
<td><strong>Data/sample</strong> <em>(description of data/sample and size)</em>: no other data sources available</td>
</tr>
<tr>
<td>2g.2</td>
<td><strong>Analytic Method</strong> <em>(type of analysis &amp; rationale)</em>:</td>
</tr>
<tr>
<td>2g.3</td>
<td><strong>Testing Results</strong> <em>(e.g., correlation statistics, comparison of rankings)</em>:</td>
</tr>
<tr>
<td>2h.1</td>
<td>If measure is stratified, provide stratified results <em>(scores by stratified categories/cohorts)</em>: NA</td>
</tr>
<tr>
<td>2h.2</td>
<td>If disparities have been reported/identified, but measure is not specified to detect disparities, provide follow-up plans: Disparities have not been reported.</td>
</tr>
<tr>
<td>2</td>
<td><strong>TAP/Workgroup</strong>: What are the strengths and weaknesses in relation to the subcriteria for Scientific Acceptability of Measure Properties?</td>
</tr>
<tr>
<td>3</td>
<td><strong>Steering Committee</strong>: Overall, to what extent was the criterion, Scientific Acceptability of Measure Properties, met?</td>
</tr>
<tr>
<td>3a.1</td>
<td><strong>Current Use</strong>: In use</td>
</tr>
<tr>
<td>3a.2</td>
<td>Use in a public reporting initiative <em>(disclosure of performance results to the public at large)</em> <em>(If used in a public reporting initiative, provide name of initiative(s), locations, Web page URL(s). If not publicly reported, state the plans to achieve public reporting within 3 years)</em>: Data from SVS VQI and VSGNE are reported to each hospital and provider in a format that can be transmitted to an appropriate public reporting mechanism.</td>
</tr>
</tbody>
</table>
3a.3 If used in other programs/initiatives (If used in quality improvement or other programs/initiatives, name of initiative(s), locations, Web page URL(s). If not used for QI, state the plans to achieve use for QI within 3 years):

Vascular Study Group of New England www.vsgne.org

Data have been successfully collected in this quality registry since 2003, and reports provided to participating physicians and hospitals about their rates of outcomes. These results are used by the regional quality group to provide benchmark reporting, and to stimulate regional quality improvement projects.

Testing of Interpretability (Testing that demonstrates the results are understood by the potential users for public reporting and quality improvement)

3a.4 Data/sample (description of data/sample and size): VSGNE samples previously described

3a.5 Methods (e.g., focus group, survey, QI project):
Semi-annual meetings of providers in VSGNE

3a.6 Results (qualitative and/or quantitative results and conclusions):
Benchmark reports of this outcome measure have been provided to VSGNE member physician and hospitals since 2003, and discussed at semi-annual meetings. There have been no questions about interpretability.

3b/3c. Relation to other NQF-endorsed measures

3b.1 NQF # and Title of similar or related measures:

(for NQF staff use) Notes on similar/related endorsed or submitted measures:

3b. Harmonization
If this measure is related to measure(s) already endorsed by NQF (e.g., same topic, but different target population/setting/data source or different topic but same target population):

3b.2 Are the measure specifications harmonized? If not, why?

3c. Distinctive or Additive Value
3c.1 Describe the distinctive, improved, or additive value this measure provides to existing NQF-endorsed measures:

5.1 If this measure is similar to measure(s) already endorsed by NQF (i.e., on the same topic and the same target population), Describe why it is a more valid or efficient way to measure quality:

TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Usability?

Steering Committee: Overall, to what extent was the criterion, Usability, met?

Rationale:

4. FEASIBILITY

Extent to which the required data are readily available, retrievable without undue burden, and can be implemented for performance measurement. (evaluation criteria)

4a. Data Generated as a Byproduct of Care Processes

4a.1-2 How are the data elements that are needed to compute measure scores generated?
Data generated as byproduct of care processes during care delivery (Data are generated and used by healthcare personnel during the provision of care, e.g., blood pressure, lab value, medical condition),
<table>
<thead>
<tr>
<th>Coding/abstraction performed by someone other than person obtaining original information (E.g., DRG, ICD-9 codes on claims, chart abstraction for quality measure or registry)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>4b. Electronic Sources</strong></td>
</tr>
</tbody>
</table>
| **4b.1 Are all the data elements available electronically?** *(elements that are needed to compute measure scores are in defined, computer-readable fields, e.g., electronic health record, electronic claims)*  
Yes |
| **4b.2 If not, specify the near-term path to achieve electronic capture by most providers.** |
| **4c. Exclusions** |
| **4c.1 Do the specified exclusions require additional data sources beyond what is required for the numerator and denominator specifications?**  
No |
| **4c.2 If yes, provide justification.** |
| **4d. Susceptibility to Inaccuracies, Errors, or Unintended Consequences** |
| **4d.1 Identify susceptibility to inaccuracies, errors, or unintended consequences of the measure and describe how these potential problems could be audited. If audited, provide results.**  
Size measurements of AAA should not significantly impact the measure, and symptom status is easily validated during chart review. We have not found inaccuracy in this measure. |
| **4e. Data Collection Strategy/Implementation** |
| **4e.1 Describe what you have learned/modified as a result of testing and/or operational use of the measure regarding data collection, availability of data/missing data, timing/frequency of data collection, patient confidentiality, time/cost of data collection, other feasibility/implementation issues:**  
In the VSGNE experience which has been tracking hospital mortality as a major endpoint since 2003, we have not experienced any difficulty with obtaining data related to this endpoint. Our percent missing for this variable has been less than 1%.  
**4e.2 Costs to implement the measure** *(costs of data collection, fees associated with proprietary measures):*  
In the context of the VSGNE and SVS VQI registries, there is no additional cost as all of these data are already collected. |
| **4e.3 Evidence for costs:** |
| **4e.4 Business case documentation:** |
| **TAP/Workgroup: What are the strengths and weaknesses in relation to the subcriteria for Feasibility?** |
| **Steering Committee: Overall, to what extent was the criterion, Feasibility, met?** |
| **Rationale:** |
| **RECOMMENDATION** |
| *(for NQF staff use) Check if measure is untested and only eligible for time-limited endorsement.* |
Steering Committee: Do you recommend for endorsement?  

Comments:  

| Y | N | A |

CONTACT INFORMATION

Co.1 Measure Steward (Intellectual Property Owner)  
Co.1 Organization  

Co.2 Point of Contact  
Sarah, Murphy, Staff, smurphy@vascularsociety.org, 312-334-2305-

Co.3 Measure Developer if different from Measure Steward  
Co.3 Organization  

Co.4 Point of Contact  
Sarah, Murphy, Staff, smurphy@vascularsociety.org, 312-334-2305-

Co.5 Submitter if different from Measure Steward POC  
Sarah, Murphy, Staff, smurphy@vascularsociety.org, 312-334-2305-, Society for Vascular Surgery

Co.6 Additional organizations that sponsored/participated in measure development

ADDITIONAL INFORMATION

Workgroup/Expert Panel involved in measure development  
Ad.1 Provide a list of sponsoring organizations and workgroup/panel members’ names and organizations. Describe the members’ role in measure development.

Ad.2 If adapted, provide name of original measure:  
Ad.3-5 If adapted, provide original specifications URL or attachment

Measure Developer/Steward Updates and Ongoing Maintenance  
Ad.6 Year the measure was first released: 2010  
Ad.7 Month and Year of most recent revision: 12, 2010  
Ad.8 What is your frequency for review/update of this measure?  
Ad.9 When is the next scheduled review/update for this measure?

Ad.10 Copyright statement:

Ad.11 Disclaimers:

Ad.12 -14 Additional Information web page URL or attachment:

Date of Submission (MM/DD/YY): 12/14/2010
**Open AAA Repair**

<table>
<thead>
<tr>
<th>Last Name</th>
<th></th>
<th>First Name</th>
<th></th>
<th>MI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of Birth</td>
<td>MRN</td>
<td>SSN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### General Information

- **Zip Code**
- **Ethnicity**
- **Gender**
- **Height** in inches or cm
- **Weight** lbs or kg
- **Visit code (not required)**
- **Admit Date**
- **Surgeon**
- **Discharge Status**
- **Discharge Date**
- **Surgical Date**
- **Does the patient have Medicare Part B?**
  - Never
  - Prior (>1 yr)
  - Current (within yr)

### Demographics

- **Smoking**
- **Diabetes**
- **CAD symptoms**
- **CHF**
- **Dialysis**
- **Stress Test**
- **ASA Class**
- **Previous arterial**
  - Bypass
  - Aneur Repair
- **Major Amp**
- **Pre-Op Medications**
  - ASA
  - Statin
- **Hypertension**
- **Beta blockers**
- **CABG/PTCA**
- **Creatinine**
- **Pre-op Hemoglobin**
- **ASA Class**
- **Hemoglobin**
- **Pre-op Living**
- **Medication**
- **Pre-op Living**
- **Medication**

**Notes:**
- If dead, date of death
- Transferred from:
  - Home
  - Rehab Unit
  - Nursing Home
  - Dead
  - Other Hospital
  - Skilled Nursing Facility
### History

#### Symptoms

- Family History of AAA: [ ] no; [ ] yes
- Ejection Fraction: [ ] <30%; [x] 30-50%; [ ] >50%; [ ] not do; [ ] unknown
- Iliac Aneurysm: [ ] unilateral; [ ] bilateral;
- Urgency: [ ] elective; [ ] symptomatic; [ ] ruptured

#### Fill out the fields below if Urgency equals ruptured.

- Lowest pre-intubation BP: ____________ mmHg
- Cardiac Arrest: [ ] no; [x] yes
- Time: Admission to Incision: ____________ hours

#### Procedure

- Anesthesia: [ ] general; [ ] general & epidural;
- Exposure: [ ] anterior; [ ] retroperitoneal; [ ] Distal Anastomosis
- Graft Type: [ ] dacron, woven; [ ] dacron, knitted; [ ] PTE; [ ] non-autologous biologic;
- IMA at Completion: [ ] occluded; [ ] ligated; [ ] reimplemented;
- Mannitol: [ ] no; [x] yes
- Autotransfusion: [ ] no; [x] yes
- Total Procedure Time: ____________ minutes
- Heart Rate: ____________ bpm
- On Arrival in OR: ____________ bpm

#### Concomitant Procedure:

- Thromboembolectomy: [ ] no; [x] yes
- Renal Bypass: [ ] no; [x] yes
- Infrarenal Bypass: [ ] no; [x] yes

#### Post-Op Data

- Time to Extubation: [ ] in OR; [ ] <12 hrs; [ ] 12-24 hrs; [ ] >24 hrs;
- Transfusion # Units PRBC: ____________ of units transfused
- CHF: [ ] no; [x] yes
- Leg Ischemia/Emboli: [ ] no; [x] yes, rx w/o surgery;
- Return to OR: ____________ minutes
- Stroke: [ ] none; [ ] minor; [ ] major; [ ] bleeding
- Discharge Medications: [ ] ASA; [ ] Plavix
- Peri-Op Antibiotic Ordered?: [ ] Start <1 hr Pre-op; [ ] 1st-2nd Gen Cephalosporin

#### Other

- Vasopressors required post-op: [ ] no; [x] yes
- Myocardial Infarction: [ ] troponin c
- Respiratory: [ ] pneumonia; [ ] ventilator
- Bowel Ischemia: [ ] treated conservatively; [ ] return to OR;
- Bleeding: [ ] no; [x] yes
- Statin: [ ] no; [x] yes
- Beta Blocker: [ ] no; [x] yes
- ASA: [ ] no; [x] yes
- Plavix: [ ] no; [x] yes

#### Other

- ICU Stay: ____________ days
- Dysrhythmia (new): [ ] no; [x] yes
- Change of Renal Function: [ ] creat. Increase > 0.5 mg/dl (44.2 μmol/L);
- Wound Complication: [ ] superficial separation/infection
- Return to OR: ____________
<table>
<thead>
<tr>
<th>General Information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Date of Contact</strong></td>
<td>Contact By:</td>
</tr>
<tr>
<td><strong>Current Living Status</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Current Medications</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Number of subsequent operations related to AAA</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Performed for:</strong></td>
<td></td>
</tr>
</tbody>
</table>

### Open AAA Repair - Follow-up

Last Name:  
First Name:  
DOB:  
MRN:  
SSN:  
Visit Code:  
Surgeon:  
Surgery Date:  
Zip/Postal Code:  
Side:  

**General Information**

| Date of Contact |  |
| Side:  |  |
| **Date of Death** |  |
| **Current Medications** |  |
| **ASA** |  |
| **Beta Blocker** |  |
| **Number of subsequent operations related to AAA** |  |
| **Performed for:** |  |

- ASA: [ ] No; [ ] Yes; [ ] Intolerant
- Beta Blocker: [ ] No; [ ] Yes; [ ] Intolerant
- Plavix: [ ] No; [ ] Yes; [ ] Intolerant
- Statin: [ ] No; [ ] Yes; [ ] Intolerant
- Coumadin: [ ] No; [ ] Yes; [ ] Intolerant
- Graft: [ ] No; [ ] Yes
- Incision: [ ] No; [ ] Yes
- Intestine: [ ] No; [ ] Yes
- Leg Ischemia: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
- Operation Related: [ ] No; [ ] Yes
- Non-Related: [ ] No; [ ] Yes
- Intolerance: [ ] No; [ ] Yes
OPEN INFRARENAL AAA DEFINITIONS – v.01.09

If more than one response applies, select the most severe (highest number) response for each data field.

**Pre-op**

Smoking: Prior = quit ≥ 1 year ago. Current = still smoking within last 12 months. Include cigarettes, pipe, or cigar.

HTN (Hypertension): Defined as ≥ 140/90, either systolic or diastolic, at admission or within last 6 months, or clearly documented in medical record.

Beta-blockers: Peri-operative = started within one month before surgery or during surgery. Chronic = more than one month before surgery.

CAD Symptoms (Coronary artery disease): Stable angina = stable pattern or symptoms with or without anti-anginal medication. Unstable angina = new onset, increasing frequency, lasting > 20 min and/or rest angina.

CABG/PITA: Coronary artery bypass, angioplasty, or stent.

CHF (Congestive Heart Failure): Documented CHF: Mild = SOB on exertion; Severe = SOB at rest, pulmonary edema, or pitting ankle edema. (Use 2 = mild if severity not documented.)

COPD: Not treated = COPD documented in record but not treated with medication. Meds include theophylline, aminophylline, inhalers or steroids

Dialysis: Transplant = patient has functioning kidney transplant; Dialysis = currently on hemo- or peritoneal dialysis.

Creatinine: Last available measurement taken before procedure. If multiple measurements, use highest within 30 days of surgery.

Stress Test: Includes stress EKG, stress echo, nuclear stress scans, within 2 years of surgery.

Pre-admin living: Use last living status before any current, acute hospitalization or rehab unit.

**Previous Arterial:**

- **Bypass** - Any non-cardiac arterial bypass for occlusive disease
- **CEA** - Carotid endarterectomy
- **Aneurysm Repair** – Any known true arterial aneurysm repair (excluding cerebral or pseudo-aneurysm)
- **PTA/Stent** – Of any non-cardiac artery
- **Major Amputation** – Any amputation above the foot or hand

**Pre-Op Medications:** Taken within 36 hours of surgery. Statins include any HMG-CoA reductase inhibitor, such as Lipitor, Mevacor, Pravachol, Zocor, Lescol, etc. If Plavix is discontinued prior to surgery it should be coded = 0.

**Pre-op Hemoglobin:** Most recent pre-op hemoglobin within past 30 days.

**Family history of AAA:** First-degree relative (parents, sibling, aunt, uncle, child)

**Prior Aortic Surgery:** AAA = infrarenal aneurysm repair. SAAA = Suprarenal aneurysm repair. Bypass = A-1 or A-F for occlusive disease. Other = endarterectomy or other.

**Ejection Fraction:** Left ventricular ejection fraction (%), by Echo, nuclear scan, or cath estimate, within 6 months

**Maximum AP AAA diameter:** Largest AP diameter. If AP not specified, use largest diameter. If multiple imaging modalities, use most accurate in following hierarchy: CT>MRI>Echo>arteriogram.

**Iliac aneurysm:** Iliac diameter > 1.5 cm. Maximum diameter of largest iliac artery, common, or internal.

**Procedure**

**Urgency:** Symptomatic = surgery within 24 hours of pain and/or tenderness without rupture. Ruptured = diagnosis at operation.

**Conversion from endovascular:** Early = within 30 days, late = >30 days

**Renal/visceral ischemic time:** Include any aortic re-clamp time for hypotension.

**Exposure:** Anterior = transperitoneal

**Distal anastomosis:** Most distal extent of either right or left limb if bifurcated.

**Graft Diameter:** Body size = diameter of most proximal portion of graft.

**Total procedure time**:
- From incision to closure.

**Concomitant Procedure**

**Thromboembolectomy:** For inadequate limb perfusion after initial completion of distal anastomosis via Fogarty or extension of graft (bypass).

**Ruptured AAA Repairs Only**

**Lowest pre-intubation BP:** After arrival at hospital (lowest prior to intubation). Use systolic pressure.

**Mental status:** Normal alert and oriented; Disoriented to person, place, or time.

**Delayed closure:** Fascia not closed at initial operation to avoid compartment syndrome.

**Post-op Data**

**Time to extubation:** In OR; otherwise, beginning upon departure from OR

**Vasopressor Required Pre-op:** Dopamine≥5mcg/kg/min, or neosynepherine, levophed, epinepherine, vasopressin, or other IV vasopressor during hospitalization.

**ICU stay:** Any portion of 24 hours = 1 day.

**Transfusion:** Total of all PRBC transfusions pre-op, intra-op, and post-op during this hospitalization.

**Myocardial Infarction:** Tropomin: by local standards for MI. EKG: new Q waves, new ST and T wave changes. Clinical: documentation of MI by clinical criteria or Echo or other imaging modality.

**Dysrhythmia:** New rhythm disturbance requiring treatment with medications or cardioversion.

**CHF:** Pulmonary edema with requirement for monitoring or treatment in ICU.

**Respiratory:** Pneumonia = Lobar infiltrate on CXR and pure growth of recognized pathogen or 4+ growth of recognized pathogen in presence of mixed growth. Ventilator = required after initially extubated (if applicable).

**Change renal function:** New increase in creatinine of 0.5mg/dl. New dialysis includes peritoneal dialysis, hemodialysis, and hemo-filtration. (Applies to dialysis only if not required pre-op.)

**Leg ischemia/emboli:** Loss of previously palpable pulses, loss of previously present Doppler signals, decrease of >0.15 in ABI, or blue toe.

**Bowel ischemia:** Diagnosed by colonoscopic evidence of ischemia, bloody stools in a patient who dies prior to colonoscopy or laparotomy, or presumptive diagnosis with conservative treatment.

**Peri-operative Antibiotics:** Use 8=no if antibiotic was not ordered. To use 1=yes, antibiotic must be ordered to be given within 1 hour prior to skin incision and must be ordered to be discontinued within 24 hrs of end of time of operation. To use 2=no for medical reason, a medical reason must be documented in the chart that antibiotic not given. **Acceptable antibiotics include:** Ampicillin/sulbactam, Aztreonam, Cefazolin, Cefmetazole, Cefotetan, Cefuroxime, Ciprofloxacin, Clindamycin, Ertapenem, Erythromycin base, Gatifloxacin, Gentamicin, Levofloxacin, Metronidazole, Moxifloxacin, Neomycin, and Vancomycin.

**1st-2nd Generation Cephalosporin:** (Cefazolin or Cefuroxime) Use response 1=yes, if ordered. If documented in medical record that not ordered for medical reason use 2. Otherwise use 0=no.